15 avril 2020
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.690.0724
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32301306
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_598B6C57EC113
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
L. Rochat Stettler et al., « Risques infectieux des nouveaux biologiques immunosuppresseurs : quelles prophylaxies et quand ? [Infectious risks of new immunosuppressive biologicals : which prophylaxis and when ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.690.0724
Biological treatments are a revolution in the management of many diseases and their development, with the marketing of many new biologics, challenges practitioners in assessing the risk of infectious complications. A rigorous evaluation is required with the introduction of prophylaxis, vaccinations or specific clinical monitoring.